Furiex Pharmaceuticals Inc

Furiex Pharmaceuticals — Technical Presentation (May 2014)

22 slides from Furiex Pharmaceuticals's technical presentation, May 7, 2014

  1. Slide 1: Eluxadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

    Eluxadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome Results of 2 Randomized, Double-blind, Placebo-Controlled Phase III Clinical Trials of Efficacy and Safety From Digestive Disease Week 2014

  2. Slide 2: Eluxadoline for IBS-D

    Eluxadoline for IBS-D ¢ Mixed mu (u) opioid receptor agonist/ delta (6) opioid receptor antagonist « Low systemic absorption and bioavailability - Low potential for drug-drug interactions « Animal studies suggest eluxadoline should improve the diarrheal symptoms of IBS-D with limited constipation an

  3. Slide 3: Eluxadoline Phase III Studies (3001 & 3002)

    Eluxadoline Phase Ill Studies (3001 & 3002) Goal: To assess the efficacy and safety of eluxadoline in men and women with IBS-D * Two randomized, double-blind, double-dummy, PBO controlled trials (3001 & 3002) « 556 investigators (predominantly US) ¢ Each study had three treatment arms * 75mg bid; 10

  4. Slide 4: Study Outlines

    Study Outlines Trial 3001 Prescreen Screening Double-blind Treatment Post-Tx (S$ 1 wk) (2-3 wks) (52 wks) (2 wks) Randomization Efficacy 12 wks Efficacy 26 wks End of (ay 1) Treatment Trial 3002 Prescreen Screening Double-blind Treatment Blinded PBO (S§1wk) — (2-3 wks) (26 wks) Withdrawal (4 wks) Ra

  5. Slide 5: Inclusion and Exclusion Criteria

    Inclusion and Exclusion Criteria ¢ IBS-D as defined by Rome Ill * Two week baseline - Bristol stool score (BSS) 2 5.5 (scale 1-7) - Worstabdominal pain (WAP*') > 3.0 (scale 0-10) - Global symptom score (GSS?) = 2.0 (scale 0-4) Additional requirements: - Diary compliance - No rescue medications durin

  6. Slide 6: Primary Composite Endpoints

    Primary Composite Endpoints * Tobea respondera patient MUST meet BOTH responder criteria on > 50% of days: - Daily pain responder: Worst abdominal pain (WAP) scores in the past 24 hours improved by 2 30% compared to average baseline pain - Daily stool consistency responder: Bristol Stool Score (BSS)

  7. Slide 7: Enrollment and Baseline Characteristics

    Enrollment and Baseline Characteristics 3001 3002 3001 3002 mean (SD) mean (SD) Screened 2832 2521 Bss* 6.3 (0.4) 6.2 (0.4) Randomized 1281 1146 WapP* 6.2 (1.5) 6.0 (1.5) Mean Age 44.9 (13.7) 45.9 (13.5) #BMs/day| 4.9 (2.8) 4.8 (3.0) Female 838 (65.4%) | 768 (67.0%) oe Ze) ane) >65 years 115 (9.0%)

  8. Slide 8: Primary Endpoint: FDA (Weeks 1-12)

    Primary Endpoint: FDA (Weeks 1-12) 3001 3002 Pooled e P=014 P= 004 P<.001 Pp <.001 P<.001 P< 001 Lea A=103 Aone A=127 8 A=95 = a ie 28 i | | I L I IL 10 17.1% Pee 16.2% 16.7 % Po n-427 0-426 n=427 n=381 n=382 n=382 n=808

  9. Slide 9: Primary Endpoint: EMA (Weeks 1-26)

    Primary Endpoint: EMA (Weeks 1-26) 3001 3002 Pooled A= 125 A=115 A=102 3 A A=44 jal | | J i| il [ é ° 19 % (20.2% 19.5 % ° Poo Poo 75mg ‘100mg, Peo ‘00mg eae ee re ee

  10. Slide 10: Daily Composite Response

    Daily Composite Response Weeks 0-26 (Pooled) Percentage of Dally Composite Responders I ke cide ae ots Pe NA ~ BNR AING, LAREN CS, i ANNIE Doe, SEALE Va \ v Sunny" ‘ MS, Oe ae v frye Zo {Sania aaa kh ad aki i a ed a a ek A A al A GM ib BA a 7 14 21 28 35 42 49 56 63 70 77 84 91 98 105 112 119 126 13

  11. Slide 11: Efficacy on Primary Composite Endpoint by Gender (pooled)

    Efficacy on Primary Composite Endpoint by Gender (pooled) Males Females 100mg Pbo pvalue 100 mg Pbo pvalue n=268 n=282 n=538 n=527 Weeks 1-12 | 26.10% 15.20% 0.002 27.50% 17.50% <0.001 Weeks 1-26 | 31.70% 19.10% <o.001 30.70% 19.70% <0.001 il

  12. Slide 12: Pre-Specified Secondary Endpoints

    Pre-Specified Secondary Endpoints 2

  13. Slide 13: Individual Components of the Primary Endpoint

    Individual Components of the Primary Endpoint * Pain responder Stool Consistency (30% improvement) responder % Responders p value % Responders p value Weeks 1-12 100 mg 46.8% 0.069 34.7% <0.001 PBO 42.3% 21.5% Weeks 1-26 100mg 48.3% 0.086 36.8% <0.001 PBO 44.0% 23.9% 1 Pooled Studies 13

  14. Slide 14: Pain Improvement

    Pain Im ovement! | PBO 2 30% Daily Pain 2 40% Daily Pain Subject has 30%, 40% or 50% improvement of worst abd. pain vs. baseline avg) for 50% of days in study 2 50% Daily Pain a 100 mg Eluxadoline Placebo Proportion of Pain Responders for pain improvement tt 1 1 1 10 20 30 40 50 60 70 80 90 100 r re

  15. Slide 15: Adequate Relief of IBS Symptoms: 50% Responder Analysis

    Adequate Relief of IBS Symptoms: 50% Responder Analysis‘ 3001 3002 % responders p value % responders p value Weeks 1-12 | 100 mg 54.20% 0.002 58.40% 0.011 PBO 43.8% 49.2% 0.006 Weeks 1-26 | 100 mg 49.50% 0.005 53.70% PBO 40.00% 43.70% 1 Pt. asked each week (1-26): “Have you had adequate relief of yo

  16. Slide 16: Efficacy Demonstrated with Additional Secondary Endpoints

    Efficacy Demonstrated with Additional Secondary Endpoints Secondary Endpoint (% responders) 100 mg PBO pvalue* >50% Urgency Free Days (Wks 1-12) 42% 29% <0.001 >75% Urgency Free Days (Wks 1-12) 21% 12% <0.001 Secondary Endpoint (least square means) A baseline 100 mg PBO pvalue* IBS-QOL Scores! : Wk

  17. Slide 17: Summary: Adverse Events (pooled)

    Summary: Adverse Events (pooled) 75mg 100 mg PBO n=807 n=859 n=808 l# Pts (%) with AE 466(57.7) 477 (55.5) 427 (52.8) H# Pts (%) with SAE 28 (3.5) 38 (4.4) 22(2.7) Most Common! AEs: N (%) Constipation? 60 (7.4) 71 (8.3) 19 (2.6) Nausea 63 (7.8) 63(7.3) 39(4.8) Abdominal Pain? 46 (5.7) 59 (6.9) 31 (3

  18. Slide 18: Symptomatic Hepatobiliary Events of Sphincter of Oddi Spasm

    Symptomatic Hepatobiliary Events of Sphincter of Oddi Spasm 8 adjudicated cases of hepatobiliary sphincter of Oddi spasm (epigastric or biliary pain, transaminase 1, often w/nausea). Bilirubin, alk phosph, lipase unremarkable 8/8 patients had prior cholecystectomy’ 6/8 noted symptoms during 1st week

  19. Slide 19: Pancreatitis

    Pancreatitis ¢ 5 cases adjudicated as pancreatitis by external committee (Atlanta criteria definition’). ¢ All cases adjudicated as mild (Atlanta Criteria’) ¢ Rate in Phase III is ~0.3% of eluxadoline treated patients ¢ All subjects w/ pancreatitis had risk factors which may have predisposed - Hx of

  20. Slide 20: Pancreatitis (continued)

    Pancreatitis (continued) Rapid declines in lipase, brief hospitalizations No sequelae Pancreatitis likely due to increased contractility at sphincter of Oddi - Locally / topically mediated as eluxadoline transits the Gl tract - Eluxadoline has low systemic availability - Duodenal concentrations in e

  21. Slide 21: Conclusions

    Conclusions Eluxadoline is a 1* in class, oral, locally-acting drug candidate for IBS-D, with a novel mechanism Efficacy demonstrated in two Phase Ill studies (for both FDA & EMA endpoints): - Significantimprovements in 1 ° composite endpoint (simultaneous improvement in both pain & diarrhea) - Effe

  22. Slide 22: Acknowledgments

    Acknowledgments We thank the study investigators, their staff and the IBS-D patients participating in the eluxadoline Phase Ill studies. Furiex Pharmaceuticals Contributors* Paul Covington Scott Dove Dave Andre Lisa Turner Mike Davenport Rocio Lopez June Almenoff Michelle Usher Tim Costello Gail Mci

Furiex Pharmaceuticals — Technical Presentation (May 2014) on 6ix